Psoriatic Disease

SCOTTSDALE, Ariz. — Understanding patients’ disease burden and priorities can help rheumatologists choose the best therapy for psoriatic arthritis, noted a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.

Water-free, lipid-based spray formulations of calcipotriol were efficacious and safe in psoriasis vulgaris treatment and could potentially increase treatment adherence among patients, according to a study.

The 2-year safety profile of guselkumab appears consistently favorable across patients with psoriatic arthritis who are either naïve or experienced with TNF inhibitors, according to data published by The Journal of Rheumatology.

WAILEA, Hawaii — Bolstered by Mendelian randomization studies linking coronary artery disease and psoriasis, researchers are exploring how to combat cardiovascular events in patients with psoriatic disease, according to a presenter here.

Ustekinumab and TNF inhibitors demonstrate comparably persistent effects at 3 years in patients with psoriatic arthritis, but with fewer adverse events in those receiving ustekinumab, according to data.

Patients with psoriatic arthritis demonstrate a “substantial prevalence” of radiographic damage at baseline, which is related to time since diagnosis, according to data published in Arthritis Research and Therapy.

In 2021, Humira, the blockbuster biologic that has for years been the highest grossing drug in the world, accomplished something that no drug had previously achieved when its global revenues topped $20 billion.

PHILADELPHIA — While over half of referrals generated by results from a home-screening survey for psoriatic arthritis were deemed appropriate, the rate of an actual diagnosis was low, according to results of a study.

The FDA has approved Idacio as the eighth biosimilar to adalimumab, for all eligible indications of the reference product, clearing the way for its U.S. release in 2023 alongside a deluge of other Humira biosimilars.

Patients with psoriatic arthritis who receive tofacitinib demonstrate “sustained improvements” in dactylitis compared with those who did not receive tofacitinib, according to data published in BMC Rheumatology.